Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsGLP-1 & Metabolic

Pemvidutide (ALT-801) Dosing Protocol: 1:1 GLP-1/Glucagon Guide

Also known as: ALT-801, Altimmune 1:1 GLP-1/Glucagon Agonist

Dose Range
1.2–1.8 mgResearch range
0Typical research window: 1.2–1.8 mg2.5 mg

Studied in published research — not a medical recommendation. Primary protocol (MOMENTUM Phase 2b Obesity & Lean-Preservation Protocol): 1.2 mg or 1.8 mg weekly (no titration) or 2.4 mg weekly (after 4-week ramp), Once weekly.

Protocol at a Glance
How Often
Once weekly

Once weekly

A Typical Run
24–48 weeks

Research-reported range (no primary dosing study). 2.4 mg dose achieved 15.6% mean weight loss at 48 weeks with 78.1% of weight loss derived from fat tissue

How It's Taken
Vial

Subcutaneous injection

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u10u20u30u40u50u
Low end: 1.2 mg48 units
High end: 1.8 mg72 units

All U-100: 100 units = 1 mL. 4 doses in the vial at the low end (2 doses at the high end).

Track the doses you run

Save Pemvidutide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Dual GLP-1 & Hepatic Glucagon Receptor Co-Agonist (Oxyntomodulin Class)
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

Bottom Line Up Front

Pemvidutide (ALT-801) is a balanced 1:1 GLP-1/Glucagon dual receptor agonist by Altimmune. Phase 2b MOMENTUM showed 15.6% weight loss at 48 weeks with 78.1% of weight lost from adipose tissue (only 21.9% lean mass), plus 68.5% liver fat reduction in the IMPACT MASH trial.

Best evidence for

Hepatic fat clearance (MASH) and obesity weight loss with superior lean muscle preservation

Weakest evidence for

Glycemic HbA1c reduction in severe insulin-dependent Type 2 diabetes vs pure GIP/GLP-1 agonists

Pharma equivalent

ALT-801 (Altimmune — Investigational Phase 2b/3)

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Pemvidutide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Pemvidutide is a 29-amino-acid peptide engineered with an equimolar (1:1) potency ratio at human GLP-1 and Glucagon receptors, conjugated to a proprietary glycolipid surfactant domain that slows subcutaneous absorption and binds serum albumin. Because its absorption profile avoids sharp Cmax spikes, Pemvidutide can be administered at 1.2 mg and 1.8 mg weekly without multi-month dose titration, while closely mimicking the physiological metabolic effects of endurance exercise and ketogenic fat oxidation.

Mechanisms of Action

  • 1:1 balanced agonism at GLP-1R (central satiety & caloric reduction) and GCGR (hepatic beta-oxidation & thermogenesis)
  • EuPort glycolipid surfactant attachment slows peak plasma Cmax after SubQ injection, improving tolerability without mandatory titration at 1.2–1.8 mg
  • Preserves skeletal muscle mass during caloric deficit: MRI body-composition sub-studies showed 78.1% fat mass loss vs only 21.9% lean mass reduction
  • Directly mobilizes intrahepatic triglycerides, reducing liver fat by up to 68.5% by MRI-PDFF within 24 weeks

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
MOMENTUM Phase 2b Obesity & Lean-Preservation Protocol
reported protocol
1.2 mg or 1.8 mg weekly (no titration) or 2.4 mg weekly (after 4-week ramp)Once weekly24–48 weeksSubcutaneous injectionclinical trial—
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (Pemvidutide)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Investigational Phase 2b/3 compound — not yet FDA approved
  • •Ensure adequate dietary protein (1.6–2.0 g/kg/day) and electrolyte intake to support hepatic ketogenesis and lean mass retention
  • •Monitor ALT/AST, fasting glucose, and resting heart rate at baseline and week 6–8
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Pemvidutide, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.